Search Results - "Lisovoder, N."

Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial by Halota, W., Ferenci, P., Kozielewicz, D., Dybowska, D., Lisovoder, N., Samira, S., Shalit, I., Ellis, R., Ilan, Y.

“…Summary Orally administered anti‐CD3 antibodies are biologically active in the gut through induction of regulatory T cells, exert an immune‐modulatory effect,…”
Get full text

1202 ORAL ANTI-CD3 IMMUNOTHERAPY FOR HCV-NON-RESPONDERS IS SAFE, PROMOTES REGULATORY T CELLS, AND DECREASES VIRAL LOAD AND LIVER ENZYME LEVELS: RESULTS OF A PHASE-2a PLACEBO-CONTROLLED TRIAL by Halota, W, Ferenzi, P, Kozielewicz, D, Dybowska, D, Lisovoder, N, Samira, S, Shalit, I, Ellis, R, Ilan, Y

Get full text

Oral anti‐ CD 3 immunotherapy for HCV ‐nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase‐2a placebo‐controlled trial by Halota, W., Ferenci, P., Kozielewicz, D., Dybowska, D., Lisovoder, N., Samira, S., Shalit, I., Ellis, R., Ilan, Y.

“…Summary Orally administered anti‐ CD 3 antibodies are biologically active in the gut through induction of regulatory T cells, exert an immune‐modulatory…”
Get full text